How I investigate acute myeloid leukemia, Int J Lab Hematol, 2019. ,
, , 2019.
Cytarabine and daunorubicin for the treatment of acute myeloid leukemia, Expert Opin Pharmacother, vol.18, issue.16, pp.1765-80, 2017. ,
How can one optimize induction therapy in AML?, Best Pract Res Clin Haematol, vol.30, issue.4, pp.301-306, 2017. ,
Emerging therapies for acute myeloid leukemia, J Hematol OncolJ Hematol Oncol, vol.10, issue.1, p.93, 201718. ,
, Emerging drug profile: CPX-351 (vyxeos) in AML. -PubMed -NCBI, 2019.
, VYXEOS 44 mg/100 mg poudre pour solution à diluer pour perfusion -ANSM : Agence nationale de sécurité du médicament et des produits de santé, 2019.
, , 2020.
, Advances in treatment formulations for acute myeloid leukemia. -PubMed -NCBI, 2019.
Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia, Leuk Res, vol.36, issue.10, pp.1283-1292, 2012. ,
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia, J Clin Oncol Off J Am Soc Clin Oncol, vol.36, issue.26, pp.2684-92, 201810. ,
Acute myeloid leukemia in the older patient, Crit Rev Oncol Hematol, vol.48, pp.17-26, 2003. ,
Therapeutic advances in acute myeloid leukemia, J Clin Oncol Off J Am Soc Clin Oncol, vol.29, issue.5, pp.487-94, 2011. ,
, Laboratoire d'Hématologie Cellulaire du CHU d'Angers, 2019.
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet, Blood, vol.115, issue.3, pp.453-74, 2010. ,
, Résumé des caractéristiques du produit -CYTARABINE ACCORD 100 mg/ml, solution injectable ou pour perfusion -Base de données publique des médicaments, 2019.
, , 2019.
, Wikipédia [Internet, 2020.
An overview of cytidine deaminases, Int J Hematol, vol.83, issue.3, pp.195-200, 2006. ,
Cytidine deaminase and the development of resistance to arabinosyl cytosine, Nature New Biol, vol.233, issue.38, pp.109-119, 1971. ,
Drug sensitivity test for patients with acute leukemia on high-dose ara-C therapy, Semin Oncol, vol.12, issue.2, pp.31-34, 1985. ,
, CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine, 2019.
, intercalants : Classification Vidal, 2019.
Nouvelles approches thérapeutiques dans les leucémies aiguës myéloïdes. Rev Francoph Lab, pp.65-73, 2015. ,
Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older, J Clin Oncol Off J Am Soc Clin Oncol, vol.31, issue.3, pp.321-328, 2013. ,
, A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients, 2019.
Influence of cholesterol on the association of plasma proteins with liposomes. Biochemistry (Mosc), vol.35, pp.2521-2526, 1996. ,
, Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. -PubMed -NCBI, 2019.
Improving combination cancer therapy: the CombiPlex® development platform, Future Oncol Lond Engl, vol.14, issue.13, pp.1317-1349, 2018. ,
CPX-351 in acute myeloid leukemia: can a new formulation maximize the efficacy of old compounds?, Expert Rev Hematol, vol.10, issue.10, pp.853-62, 2017. ,
Daunorubicin and Cytarabine Liposome in Newly Diagnosed Therapy-Related Acute Myeloid Leukemia (AML) or AML With Myelodysplasia-Related Changes, Ann Pharmacother, vol.52, issue.8, pp.792-800, 2018. ,
, Preparation & Administration | VYXEOS® (daunorubicin and cytarabine
, European Medicines Agency, 2018.
, VYXEOS® Mechanism of Delivery -Secondary AML Treatment | VYXEOS® (daunorubicin and cytarabine) HCP [Internet, 2020.
Effects of flow rate on the migration of different plasticizers from PVC infusion medical devices, PloS One, vol.13, issue.2, p.192369, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01781597
, Référence 146706 -Concentrateur 5000 Daltons Vivaspin 6 -Dominique DUTSCHER -Matériel de laboratoire
Physicochemical characterization of drug nanocarriers, Int J Nanomedicine, vol.12, pp.4991-5011, 2017. ,
Simultaneous determination of cytosine arabinoside and its metabolite uracil arabinoside in human plasma by LC-MS/MS: Application to pharmacokinetics-pharmacogenetics pilot study in AML patients, J Chromatogr B Analyt Technol Biomed Life Sci, pp.1126-1127, 2019. ,
Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin, Int J Pharm, vol.391, issue.1-2, pp.248-59, 2010. ,
Mise en place d'un outil d'aide à la détection des interactions physico-chimiques en Y des médicaments injectables : analyse rétrospective des prescriptions dans un service d'hématologie. Pharm Hosp Clin, vol.54, pp.348-55, 2019. ,
Compatibility of caspofungin acetate injection with other drugs simulated y-site coadministration, Int J Pharm Compd, vol.12, issue.3, pp.276-284, 2008. ,
, King Guide IV Drug Compatibility Wall Charts, 2019.
, Physicochemical characterization of drug nanocarriers. -PubMed -NCBI, 2019.
Selection of the best blood compartment to measure cytidine deaminase activity to stratify for optimal gemcitabine or cytarabine treatment, Nucleosides Nucleotides Nucleic Acids, vol.33, pp.403-415, 2014. ,
A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias, Cancer Chemother Pharmacol, vol.84, issue.1, pp.163-73, 2019. ,
Outcomes in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML) Who Achieved Remission with CPX-351 Versus 7+3 Induction: Exploratory Analysis of a Phase 3 Study, Clin Lymphoma Myeloma Leuk, vol.19, pp.206-213, 2019. ,